Xander Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
- Paid Up Capital ₹ 2.00 M
- Company Age 12 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth %
- Profit Growth -4.02%
- Ebitda -11.21%
- Net Worth -2.93%
- Total Assets -5.66%
About Xander Pharmaceuticals
Xander Pharmaceuticals Private Limited (XPPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 March 2012 and has a history of 12 years and 11 months. Its registered office is in Malappuram, Kerala, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 2.00 M, as per Ministry of Corporate Affairs (MCA) records.
Raghunath Kolayambarampath and Kozhappilly Kutty serve as directors at the Company.
Company Details
- Location
Malappuram, Kerala, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24233KL2012PTC030714
- Company No.
030714
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Mar 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Who are the key members and board of directors at Xander Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kozhappilly Kutty  | Director | 10-May-2024 | Current |
| Raghunath Kolayambarampath | Whole-Time Director | 05-Apr-2014 | Current |
Financial Performance of Xander Pharmaceuticals.
Xander Pharmaceuticals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a slight decrease in profitability, with a 4.02% decrease in profit. The company's net worth dipped by a decrease of 2.93%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Xander Pharmaceuticals?
Unlock access to Xander Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Bio Dontia Solutions Private LimitedKozhappilly Kutty is a mutual person
- Eptas Enterprises Private Limited
Kozhappilly Kutty is a mutual person
- Sargatma Construction Private Limited
Kozhappilly Kutty is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Xander Pharmaceuticals?
Unlock and access historical data on people associated with Xander Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Xander Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Xander Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
